Comparison · NCT00121108-1a43adaf
Motavizumab vs Placebo: Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Motavizumab vs Placebo: Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI). Trial comparisons, record NCT00121108-1a43adaf. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00121108-1a43adaf
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0289 | 0.0214 | 0.039 | wilson | |
| Risk in group 2 | 0.1 | 0.08 | 0.124 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0711 | -0.0965 | -0.0487 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.289 | 0.199 | 0.42 | log | |
| Odds ratio, group 1 over group 2 | 0.268 | 0.181 | 0.398 | log | |
| Number needed to treat, for one fewer participant with the outcome on Motavizumab than on Placebo | 14.1 | 10.4 | 20.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Motavizumab | Participants received IM dose of motavizumab 15 milligram/Kilogram (mg/kg) every 30 Days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the RSV season. | 41 | 1,417 | OG001 |
| Group 2 | Placebo | Participants received intramuscular (IM) dose of placebo matched to motavizumab every 30 days for a maximum of 5 injections (on Days 0, 30, 60, 90, and 120) during the respiratory syncytial virus (RSV) season. | 71 | 710 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With RSV Outpatient Medically Attended Lower Respiratory Illness (MA LRI)
- Description
The RSV outpatient MA LRI was defined as an outpatient medically attended event designated as a lower respiratory illness with a positive RT-PCR RSV test. An LRI event is one that has a medical diagnosis of bronchiolitis or pneumonia. In the absence of such a medical diagnosis, the occurrence of LRI events was determined by the principal investigator after review of the medical record and considering the presence of cough, retractions, rhonchi, wheezing, crackles, or rales, associated with symptoms (by history or clinical findings) of coryza, fever, or apnoea.
- Time frame
- From study Day 0 through study Day 150
- Population
- The ITT population included all participants in the treatment group according to their randomized treatment group.
Source ClinicalTrials.gov
Trial
- Title
- MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States
- NCT number
- NCT00121108
- Phases
- PHASE3
- Conditions
- Healthy
- Interventions
- Motavizumab, Placebo
- Lead sponsor
- MedImmune LLC
- Results first posted
- 2022-01-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00121108?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00121108-1a43adaf